Skip to main content
Premium Trial:

Request an Annual Quote

Notable Labs, CicloMed Partner on AML Trial With Goal to ID Responders

NEW YORK – Notable Labs and biotech CicloMed said on Wednesday that they have partnered on a clinical trial evaluating CicloMed's investigational agent fosciclopirox for acute myelogenous leukemia patients.

Within the Phase IB/IIA clinical trial, Foster City, California-based Notable will use its predictive precision medicine platform to predict which patients respond to fosciclopirox. Notable's platform involves exposing patients' cancer cells to the treatment ex vivo, analyzing dynamic signals reflecting responses, and translating these findings into predictive algorithms using machine learning.

While Notable will focus on optimizing its platform for fosciclopirox sensitivity in AML, CicloMed will conduct and execute the trial operations. The firms will share financial responsibility for the study.

According to Notable CEO Thomas Bock, the firm's functional precision medicine approach to identifying best responders to treatments may speed up the clinical trial process. "Notable's unique predictive precision medicines platform has the potential to develop cancer treatments precisely for the patients predicted to respond, reducing the risks for patients of receiving treatments that don't work for them," Bock said. "Fosciclopirox is a strategically and deliberately selected program, as it has already performed well on our predictive precision medicines platform."

CicloMed, headquartered in Kansas City, Missouri, is already evaluating fosciclopirox as a single-agent therapy and in combination with chemo in relapsed or refractory AML patients. The firm is also evaluating the agent in patients with advanced solid tumors. Scientists at the University of Kansas Cancer Center originally discovered the drug, and the University of Kansas Institute for Advancing Medical Innovation teamed up with BioNovus Innovations in 2016 to launch CicloMed and develop fosciclopirox.